Alena Donda

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil

24 publications

2019 | 2018 | 2017 | 2016 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2006 | 2005 | 2003 |
MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma.
Martinez-Usatorre A., Sempere L.F., Carmona S.J., Carretero-Iglesia L., Monnot G., Speiser D.E., Rufer N., Donda A., Zehn D., Jandus C. et al., 2019/06. Cancer immunology research, 7 (6) pp. 1013-1024. Peer-reviewed.
Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control.
Botelho N.K., Tschumi B.O., Hubbell J.A., Swartz M.A., Donda A., Romero P., 2019. Frontiers in immunology, 10 p. 294. Peer-reviewed.
Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic β Cell Death and May Contribute to Type 1 Diabetes Development.
Guay C., Kruit J.K., Rome S., Menoud V., Mulder N.L., Jurdzinski A., Mancarella F., Sebastiani G., Donda A., Gonzalez B.J. et al., 2019. Cell Metabolism, 29 (2) pp. 348-361.e6. Peer-reviewed.
PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
Martínez-Usatorre A., Donda A., Zehn D., Romero P., 2018/07/15. Journal of immunology, 201 (2) pp. 792-803. Peer-reviewed.
CART cells are prone to Fas- and DR5-mediated cell death.
Tschumi B.O., Dumauthioz N., Marti B., Zhang L., Schneider P., Mach J.P., Romero P., Donda A., 2018/07/13. Journal for immunotherapy of cancer, 6 (1) p. 71. Peer-reviewed.
Correction to: CART cells are prone to Fas- and DR5-mediated cell death.
Tschumi B.O., Dumauthioz N., Marti B., Zhang L., Lanitis E., Irving M., Schneider P., Mach J.P., Coukos G., Romero P. et al., 2018. Journal for Immunotherapy of Cancer, 6 (1) p. 92. Peer-reviewed.
Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol-Rich Extract Has Opposite Effects on Tumor Growth.
Lasso P., Gomez-Cadena A., Urueña C., Donda A., Martinez-Usatorre A., Barreto A., Romero P., Fiorentino S., 2018. Frontiers in oncology, 8 p. 356. Peer-reviewed.
Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.
Zhang L., Donda A., 2017. Frontiers in immunology, 8 p. 1417. Peer-reviewed.
Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model.
Gomez-Cadena A., Urueña C., Prieto K., Martinez-Usatorre A., Donda A., Barreto A., Romero P., Fiorentino S., 2016. Cell Death and Disease, 7 (6) pp. e2243. Peer-reviewed.
Mammalian Target of Rapamycin Complex 2 Controls CD8 T Cell Memory Differentiation in a Foxo1-Dependent Manner.
Zhang L., Tschumi B.O., Lopez-Mejia I.C., Oberle S.G., Meyer M., Samson G., Rüegg M.A., Hall M.N., Fajas L., Zehn D. et al., 2016. Cell Reports, 14 (5) pp. 1206-1217. Peer-reviewed.
Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients.
Murray T., Fuertes Marraco S.A., Baumgaertner P., Bordry N., Cagnon L., Donda A., Romero P., Verdeil G., Speiser D.E., 2016. Frontiers in immunology, 7 p. 573. Peer-reviewed.
iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine.
Corgnac S., Perret R., Zhang L., Mach J.P., Romero P., Donda A., 2014. Journal for Immunotherapy of Cancer, 2 (1) p. 39. Peer-reviewed.
Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function.
Zhang L., Tschumi B.O., Corgnac S., Rüegg M.A., Hall M.N., Mach J.P., Romero P., Donda A., 2014. Journal of Immunology, 193 (4) pp. 1759-1765.
Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity.
Perret R., Sierro S., Botelho N.K., Corgnac S., Donda A., Romero P., 2013. Cancer Research, 73 (22) pp. 6597-608.
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
Corgnac S., Perret R., Derré L., Zhang L., Stirnemann K., Zauderer M., Speiser D.E., Mach J.P., Romero P., Donda A., 2013. Cancer Immunology, Immunotherapy, 62 (4) pp. 747-760.
MicroRNA-155 Is Required for Effector CD8(+) T Cell Responses to Virus Infection and Cancer.
Dudda J.C., Salaun B., Ji Y., Palmer D.C., Monnot G.C., Merck E., Boudousquie C., Utzschneider D.T., Escobar T.M., Perret R. et al., 2013. Immunity, 38 (4) pp. 742-753. Peer-reviewed.
SITC 26th annual meeting - summary.
Romano E., Nardelli-Haefliger D., Donda A., Corgnac S., Romero P., 2012. Journal of Translational Medicine, 10 (1) p. 105.
Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity.
Sierro S.R., Donda A., Perret R., Guillaume P., Yagita H., Levy F., Romero P., 2011. European Journal of Immunology, 41 (8) pp. 2217-2228.
Estrogen receptor regulates MyoD gene expression by preventing AP-1-mediated repression.
Pedraza-Alva G., Zingg J.M., Donda A., Pérez-Martínez L., 2009. Biochemical and Biophysical Research Communications, 389 (2) pp. 360-365.
Direct presentation of a melanocyte-associated antigen in peripheral lymph nodes induces cytotoxic CD8+ T cells.
Schuler P., Contassot E., Irla M., Hugues S., Preynat-Seauve O., Beermann F., Donda A., French L.E., Huard B., 2008. Cancer research, 68 (20) pp. 8410-8418. Peer-reviewed.
Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice
Stirnemann K., Romero J. F., Baldi L., Robert B., Cesson V., Besra G. S., Zauderer M., Wurm F., Corradin G., Mach J. P. et al., 2008. Journal of Clinical Investigation, 118 (3) pp. 994-1005. Peer-reviewed.
Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
Cesson V., Stirnemann K., Robert B., Luescher I., Filleron T., Corradin G., Mach J.P., Donda A., 2006. Clinical cancer research, 12 (24) pp. 7422-7430. Peer-reviewed.
MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells.
Germain C., Larbouret C., Cesson V., Donda A., Held W., Mach J.P., Pèlegrin A., Robert B., 2005. Clinical Cancer Research, 11 (20) pp. 7516-7522. Peer-reviewed.
In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.
Donda A., Cesson V., Mach J.P., Corradin G., Primus F.J., Robert B., 2003. Cancer Immunity, 3 p. 11.
Unicentre - CH-1015 Lausanne
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University